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Abstract
Hypothalamic hamartomas (HH) are rare, basilar developmental lesions with widespread
comorbidities often associated with refractory epilepsy and encephalopathy. Imaging advances
allow for early, even prenatal, detection. Genetic studies suggest mutations in GLI3 and other
patterning genes are involved in HH pathogenesis. About 50%–80% of children with HH have
severe rage and aggression and a majority of patients exhibit externalizing disorders. Behavioral
disruption and intellectual disability may predate epilepsy. Neuropsychological, sleep, and
endocrine disorders are typical. The purpose of this article is to provide a summary of the
current understanding of HH and to highlight opportunities for future research.

Introduction
Hypothalamic hamartomas (HHs) are deep-seated developmental lesions that have varied manifestations. This review is based on the 4th International Symposium on Hypothalamic Hamartomas,
which took place September 12–14, 2019, in Washington, DC, and current concepts, experience, and
research. The reader is provided a key clinical summary of HH as well as the most current recommendations for workup and diagnosis. We summarize current thinking regarding pathophysiology,
genetic underpinnings, and broad comorbidities of the disease. The surgical management of HH is
reviewed. Finally, future research and clinical priorities are considered.

Search Method
We conducted a thorough search of the literature through PubMed with the search phrase
“hypothalamic hamartoma,” identifying 770 articles, 111 of which were published from 2018 to
2021, which were reviewed for content. The subsection editors also reviewed references in their
respective sections in regard to their command of material and PubMed. We have included in our
references the major publications from the past 3 years and major publications prior to 2018.
Where relevant, we listed the most recent article or review (especially for the surgical literature)
and we recognize this is often at the expense of the original work or observation. Those important
references will be found in the articles’ citations.
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Glossary
ADHD = attention-deﬁcit/hyperactivity disorder; GKS = Gamma Knife radiosurgery; HH = hypothalamic hamartoma; HOS =
hypothalamic obesity syndrome; LGG = low-grade glioma; LITT = laser interstitial thermal therapy; LTN = lateral tuberal
nucleus; PHS = Pallister-Hall syndrome; SRT = stereotactic radiofrequency thermocoagulation; SUDEP = unexplained death
in epilepsy.

Clinical Summary
HHs are lesions of varying size that arise in the ventral
hypothalamic region. They are commonly associated with
diverse neurologic, endocrinologic, cognitive, behavioral,
and psychiatric comorbidities, including epilepsy, epileptic
encephalopathy, precocious puberty, and rage. There are 2
classic clinical phenotypes of HH, intrahypothalamic and
parahypothalamic, and each is associated with a typical
clinical spectrum. Intrahypothalamic HH is associated with
epilepsy with gelastic and other seizure types and is often
pharmacoresistant. The HH syndrome may include the
evolution of developmental regression, psychiatric and
behavioral comorbidities, and precocious puberty.1 Parahypothalamic HH is usually only associated with endocrinopathy, such as precocious puberty. Epilepsy and
cognitive and behavioral disturbances can occur, although
rare.2
The prevalence of HH is estimated to be 1 in 200,000 children.3 The epilepsy syndrome is often associated with the
occurrence of gelastic seizures, which are episodes of uncontrollable mirthless laughter, often unrecognized in the
early years. These can evolve to include focal seizures with
impaired awareness, dacrystic (crying), atypical absence,
tonic, atonic, and generalized tonic-clonic seizures, as well as
infantile spasms.4,e1,e2,e3 Age at onset is typically less than a
year for gelastic seizures and between 2 and 7 years of age for
additional focal seizure types, both of which are often refractory to medical treatment. Due to the variable clinical
presentation, the actual prevalence of pharmacoresistant epilepsy in HH is unknown5 but has been reported in various
series between 50% and 100%; this high prevalence may
represent selection and referral bias.6,e4 Rarely, the disorder
can be mild and escape diagnosis with symptoms such as “a
pressure to laugh” in association with normal cognitive and
social development.7
The diagnostic evaluation of HH remains challenging. Due to the
depth of the lesion, scalp EEG may be falsely normal without
evidence of interictal abnormality; ictal surface EEG can be difﬁcult to localize or may be misleading.8 In one study of 133
patients with HH, 75% of 584 captured gelastic seizures (56% of
patients) had no ictal EEG change.9 The hamartoma can be
diﬃcult to identify on imaging due to its small size and location,
even by experienced neuroradiologists. A high-resolution 3T
brain MRI with epilepsy-speciﬁc protocol including thin cut 3D
T1-weighted (≤1 mm3 voxel), T2-weighted, and ﬂuid-attenuated
Neurology.org/N

inversion recovery sequences (minimum 2 planes, 3D better) will
reliably identify HHs.10,e5 The 2014 Florence consensus of the
Pediatric Epilepsy Surgery Task Force of the International League Against Epilepsy recommends ictal/interictal EEG to conﬁrm diagnosis (not for localization) as well as 3D volumetric
MRI; PET and SPECT are not recommended given signiﬁcant
false results.11 The interpretation of this imaging often requires
speciﬁc expertise, usually more readily available at skilled pediatric
epilepsy surgery centers. HH is associated with a varying
comorbidity proﬁle that includes neurodevelopmental, behavioral, and psychiatric disorders. Psychiatric comorbidities occur in
more than 50% of children.12,e6 Rage attacks, as well as less severe
aggressive behaviors and attentional problems, are common.6,13
Cognitive impairments have been reported in more than 80% of
patients, and these appear to be progressive in half of cases. In
view of the apparent relationship between the epilepsy onset and
neurocognitive diﬃculty, the syndrome is considered an epileptic
encephalopathy, with increased seizure burden contributing to
worse cognitive outcomes. Hamartoma removal or disconnection
is qualitatively linked to improved cognitive and behavioral outcomes14; single-center studies show quantitative improvements
in full-scale IQ in patients undergoing pre- and postoperative
neuropsychological testing.15
There are several hypotheses about how the encephalopathy
may develop. It may represent an ictal, interictal, or combined
phenomenon.16 The encephalopathy may be mediated by the
disruption of structural and functional hypothalamic projections including tegmental, mammillo-thalamo-cingulate, and
more distributed networks.4,e7 There may be local eﬀects
within the hypothalamus and depending on which subnuclei
are involved, with resultant endocrinologic or functional disturbances contributing to the encephalopathy, as is known to
occur in brain tumor diencephalic syndromes. This has also
been shown in PET studies in HH.e8

Pathophysiology and Imaging
The cell of origin of HH and the cause of gelastic seizures
remains unknown. HHs develop in a region rostral to the
mammillary body. A cell group in this region called the lateral
tuberal nucleus (LTN) is hypothesized to be the origin of
HH. Neuroﬁbrillary tangles are often found in HHe9 by histopathology and also in the LTN in neurodegenerative disorders such as Alzheimer disease. A similar cell group
(parvalbumin-containing cells) called PV1 lies in a homologous rodent region and has strong connections to the
Neurology | Volume 97, Number 18 | November 2, 2021
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ventrolateral periaqueductal gray.17 PV1 cells are associated
with generating species-speciﬁc vocalizations such as cackling
in monkeys. The overgrowth of LTN-derived neurons (HH)
could disinhibit PV1 neurons from their normal anterior hypothalamic inputs and may cause the laughter associated with
gelastic seizures.18 Due to the deep-seated location of the
hypothalamus and the recent frequent use of minimally invasive treatment such as laser ablation, there is a paucity of
available tissue for study. Newer techniques may allow for
tissue recovery from probes used in ablation, as has recently
been demonstrated for surgically implanted stereotactic EEG
depth electrodes.e10
Imaging allows for early detection of HH with highresolution fetal MRI. The lumen of the third ventricle is not
fully established until 26–28 weeks gestational age, so it is
diﬃcult to diagnose HH until the second trimester. A
common misdiagnosis at this time are interhypothalamic
adhesions, which are horizontally oriented bands that
connect the medial walls of the third ventricle.19 HH are
nonenhancing, may be relatively isodense, and may range in
size from 2 to 20 mm.20

Genetics
Advances have been made in the genetic underpinnings of
HH. The Sonic hedgehog (Shh) pathway regulates neurogenesis and cell patterning in early hypothalamic development; mutations in this pathway can cause increased
proliferation of nearby wild-type cells.21 Using wholeexome sequencing, chromosomal microarray, and targeted
candidate gene sequencing, somatic mutations of Shh
pathway-related genes are discovered in one third of tissue
and cell samples of patients with nonsyndromic HH.22
Similarly, germline mutations in GLI3, a transcriptional
activator and repressor of downstream Shh pathway targets, cause Pallister-Hall syndrome (PHS), a form of syndromic HH, which can be associated with polydactyly or
syndactyly, biﬁd epiglottis, imperforate anus, and renal
abnormalities.23,e11 Patients with PHS have less severe
epilepsy and fewer neuropsychiatric problems than those
with isolated HH.24
The location of variants in the GLI3 gene is associated with
diﬀerent clinical manifestations: frameshift mutations in
the middle third of the gene cause PHS, whereas those in
the ﬁrst or last third of the gene cause a distinct syndrome
called Greig cephalopolysyndactyly syndrome (poly- or
syndactyly, hypertelorism, macrocephaly), which is not
associated with HH. The mechanism of this variable presentation was demonstrated in Drosophila, which have a
homologous gene pathway to human GLI3. The location of
a frameshift mutation in GLI3 can direct whether the
downstream function of the resultant protein is activating
or repressing, and thus how a single gene mutation can lead
to various phenotypes.25
866
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An emerging concept is that HH may also develop from
biallelic germline and somatic variants within cilia, including Shh pathway genes. The cellular signaling function
of Shh proteins depends on their traﬃcking by cilia during
development.26 There is preliminary evidence for this in
several cilia genes through genetic analysis of a Japanese
HH cohort,27 and the recent discovery of a biallelic variant
in the cilia and hedgehog gene SMO in 7 patients with
broad developmental anomalies including HH.28 Demonstration of this mechanism in further cilia genes of additional nonsyndromic cases would conﬁrm that HH is a
ciliopathy. This mechanism may allow for direct therapeutic targeting.
Focus on Comorbidities
Psychiatric

HH is often complicated by psychiatric disorders, which may
occur in up to 60%–80% of pediatric cases.12 Rage attacks are a
poorly deﬁned yet fundamental element of the psychiatric proﬁle
associated with the disease.e12 In a cohort of 46 children with
hypothalamic hamartoma, almost half demonstrated rage attacks.12 These events are thought to be caused by biological
diﬃculties with emotional regulation combined with increased
aggressive tendencies; their relationship to epilepsy is unclear.
Rage attacks and autism spectrum disorder were overrepresented in the Hope for HH International Comorbidity
Survey of more than 250 international patients and families
(Soeby and Webster, unpublished data; see below). Aggressive
behavior more commonly occurs in male patients, those with
intellectual disability, those with younger age at seizure onset,
and patients with multiple seizure types.29 Other commonly
encountered psychiatric comorbidities include oppositional deﬁant disorder, attention-deﬁcit/hyperactivity disorder (ADHD),
as well as anxiety and mood disorders.30 The rates of ADHD,
anxiety disorders, and mood disorders are similar to those seen in
many other childhood onset epilepsies; similarly high rates of
depression and anxiety exist in adult patients with HH.31,32
There is no clear relationship to Delalande subtype.
Neurodevelopmental
Children with HH exhibit a variety of cognitive proﬁles from
normal to severe disability. Cognitive dysfunction may be
progressive and appears dependent on a number of factors.
Neurodevelopmental disability is more common in patients
with HH with epilepsy. Studies ﬁnd more severe cognitive
impairment in patients with earlier onset of epilepsy, increased
seizure burden, increased number of antiseizure medications,
and, for some, larger lesion burden.29,33,e13-e16 In a retrospective
study of 48 patients with HH-associated epilepsy, half of the
patients exhibited executive and 62% had verbal memory
dysfunction preoperatively. The majority of patients in this
study achieved postoperative improvements in intellectual
functioning after interstitial radiosurgery or transcallosal/
endoscopic resection.34 A study of 88 patients with HH undergoing stereotactic radiofrequency thermocoagulation surgery showed postoperative neuropsychological improved
Neurology.org/N

Table 1 Surgical Techniques for HH
Endoscopic (n = 136)

GKS (n = 135)

SRT (n = 210)

LITT (n = 101)

FUS (n = 3)

Outcomes

Engel I + II; 77%

Engel I + II; 57%

Engel I; 88%

Engel I; 93%

Engel I; 66%

Complications

Overall 8.4%
• Memory deficit 2.8%
• Oculomotor palsy 0.9%
• Motor with partial
recovery 2.35%
• Weight gain 2.35%

• Transient ↑ seizure 16.6%
• Transient temperature
instability 6.2%

None reported

• Endocrine (most common
thyroid) 11%
• Memory 2%

None reported

Who does well?

↓ Duration epilepsy

HH Class I, II, or III

↓ Duration epilepsy

Smaller lesions

N too small

Special
considerations

• Worse if preexisting
• Not for large HH
cognitive deficit
• Delayed effect (up to 2
• ↑ Complications w/larger years)
HH

• Works for all HH sizes/types • Larger HH ≥ salt wasting
• Good outcomes for
• 23% need 2nd ablation
nongelastic epilepsy

Further studies
needed

Abbreviations: FUS = focused ultrasound; GKS = Gamma Knife surgery; HH = hypothalamic hamartoma; LITT = laser interstitial thermal therapy; SRT =
stereotactic radiofrequency thermocoagulation.
Less commonly employed microsurgical techniques are discussed in the section on surgical techniques. FUS is an emerging technology and was included in
this chart for the purposes of comparison. References are in the Surgical and Therapeutic Techniques section.

performance in all patients (even in those without signiﬁcant
preoperative neurocognitive dysfunction).35 However, the relationship between seizures and cognition is unclear as there are
cases where successful surgery with regard to seizure control
may not normalize other comorbidities/encephalopathy. Early
surgery is thought to minimize the risk of encephalopathy, but
this remains untested. Many children with HH have developmental and cognitive impairments that predate the recognition of development of HH-associated epilepsy, which may
indicate these eﬀects are mediated by HH interference of
normal behavioral and memory circuitry. These issues are
further compounded by the development of intractable epilepsy, which adds to the burden of disease.12
Sleep
Patients with HH have refractory epilepsy, which can interrupt sleep, leading to an overall poor sleep quality. A cohort
of 41 patients with HH from Freiburg, Germany, had less
slow-wave sleep than healthy controls. Increased epileptic
spikes during sleep are associated with lower IQ and increased
nocturnal seizure burden worsens neuropsychological performance (Jacobs, unpublished data). Slow wave sleep has
been demonstrated to be important for memory consolidation in children with other focal epilepsies.36 As there are no
published reports on the relationship of HH and sleep, the
mechanisms underlying sleep disturbance and cognitive dysfunction remain to be elucidated.
Endocrine
The typical primary preoperative endocrinopathy associated
with HH is central precocious puberty,37 probably because of the
premature pulsatile release of hypothalamic gonadotropinreleasing hormone.6,37 Occasionally, hypogonadism or acromegaly can be seen,e17 and there is a case report of a HH
secreting corticotrophin-releasing hormone, causing elevated
serum cortisol levels.e18 Most of the other endocrine disorders
are less common and occur after treatment (e.g., postsurgical or
Neurology.org/N

radiation-induced),38 but require surveillance and follow-up. The
endocrine manifestations include diabetes insipidus,38 growth
hormone deﬁciency,e19 central hypothyroidism,38,39 and the
hypothalamic obesity syndrome (HOS).38,39 The diagnostic
workup and treatment of these endocrinopathies are in accordance with clinical practice guidelines set forth for diabetes
insipiduse20 and hypopituitarisme21 for patients without HH.
Approximately 20% of patients with HH develop the diﬃcult-totreat HOS (hyperphagia, weight gain). HOS management
strategies are based on current childhood obesity guidelines including diet and exercise, drug interventions with octreotide,40
metformin, potentially newer obesity drugs, and bariatric surgery.41 The etiology of HOS is diﬃcult to identify as there can be
premorbid obesity in up to half of patients with HH prior to
surgery. A semi-quantitative MRI-based scoring system of
damage to hypothalamic regions can help predict, based on
postoperative imaging, which patients are at risk of developing
HOS after surgery.42 Postoperative hypothalamic injury is correlated with HOS after damage to posterior hypothalamic subnuclei (such as the dorsomedial nucleus and the dorsal
hypothalamic area). These areas are involved in promotion of
energy expenditure: contributions from the dorsomedial nucleus
cause release of thyrotropin-releasing hormone from paraventricular nucleus neurons; the dorsal hypothalamic area is
involved in thermoregulation, activation of brown fat, and
locomotion.42
Quality of Life and SUDEP
Hope for HH undertook an international survey of families
including 256 respondents (mean age, 18 years; range, 1–55
years) from more than 20 countries to provide information to
inform new areas for research and clinical interventions. In
this survey, top family concerns are seizures, cognitive sequelae, future uncertainty, psychiatric and behavioral problems, inability to lead an independent life, safety, and sudden
unexplained death in epilepsy (SUDEP). Of 256 respondents,
162 had one or more surgical or radiation treatments: laser
Neurology | Volume 97, Number 18 | November 2, 2021
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Figure 1 Delalande Classification of Hypothalamic Hamartomas

Type I lesions have horizontal attachment inferior
to floor of the third ventricle. Type II lesions have
vertical attachment to the wall of third ventricle
and are above the floor of the third ventricle.
Type III lesions have horizontal and vertical attachments above and below the floor of the third
ventricle. Type IV lesions are considered “giant”
with volume 8 cm3 or larger (used with permission from Barrow Neurologic Institute, Phoenix,
AZ).

ablation (n = 61), endoscopic resection (n = 31), transcallosal
resection (n = 30), Gamma Knife (n = 27), radiofrequency
ablation (n = 27), orbitozygomatic resection (n = 9), and
other (n = 27). About half of children achieved seizure freedom. The majority of caregivers reported sleep disturbances,
including excessive daytime fatigue and sleep disruption.
Endocrine problems were common: >40% report precocious
puberty, with many others experiencing abnormal temperature regulation (40%), hypothyroidism (20%), and other
signs/symptoms of hypothalamic-pituitary-adrenal axis dysfunction. Emotional dysregulation is frequent, and a majority
of patients register rage attacks or behavioral outbursts. More
than 40% of patients received a formal diagnosis of an anxiety
disorder. A majority of patients have cognitive issues, including >60% of respondents reporting memory problems,
learning disabilities, and developmental delays. In 2019, 3
children from the Hope for HH community died of SUDEP,
raising the concern that patients with HH are at an increased
risk for SUDEP.
Surgical and Therapeutic Techniques
Several surgical approaches are used to treat HH-mediated
epilepsy depending on the location and size of HH, local
expertise, and technology available. Surgical procedures
can be classiﬁed according to their rationale (resection vs
disconnection; image-based vs functional) or type of approach (open vs minimally invasive). Table 1 summarizes
the main surgical and therapeutic techniques currently
being used to treat HH. Except for radiofrequency stereotactic disconnection, all other procedures available for
treatment of HH require some type of HH resection. An
image-based approach is preferred although some series
showed that neurophysiologic data may aﬀect outcome,
which is awaiting validation. Endoscopic and stereotactic
approaches are considered less invasive than open procedures. Endoscopic approaches might be considered more
invasive compared to stereotactic, although no head-tohead comparison is available. Morbidity is related to
number of trajectories during stereotactic procedures. One
advantage to open and endoscopic procedures is that they
can provide tissue specimens. It is arguable that lack of
tissue sampling in laser interstitial thermal therapy (LITT),
radiofrequency, focused ultrasound, or radiosurgery
868
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procedures might negatively aﬀect patient care, outcome,
and research in the future, although it may be possible to
recover DNA from cells recovered from HH probes. For
example, there are para- and intrahypothalamic hamartomas, which have diﬀerent associated morbidities. A recent
review summarizes the most updated neurosurgical data.43
The Delalande classiﬁcation system groups HH into 4 types
based on location and is in turn related to surgical trajectory/
approaches and surgical morbidities (Figures 1 and 2).44
Endoscopic resection/disconnection can be performed by
means of bipolar, radiofrequency, or laser coagulation and
achieves a high level of seizure control (up to 78% Engel I +
II) but can have an overall complication rate up to 8.3% in a
series of 112 patients.39,e22,e23 The most common adverse
outcomes were transient short term memory deﬁcit (n = 5),
oculomotor nerve palsy (transient n = 9, ongoing n = 3),
hemiplegia (n = 4), and infection (n = 4). e18 Gamma Knife
radiosurgery (GKS) has good long-term safety/eﬃcacy data,
but requires a substantial time (up to 2 years) before positive
eﬀects are seen, and is not recommended for larger HH.45,e24
In a prospective trial of 48 patients with GKS, 68.8% were
Engel I + II at last follow-up; no endocrinologic, motor, or
amnestic complications were reported.45 Stereotactic radiofrequency thermocoagulation (SRT) can be applied to
every type/size of HH with signiﬁcant reduction of gelastic
seizure burden.35,e25,e26 In a study of 100 patients with HH,
SRT led to Engel I outcome in 71% from all seizures types
with improved IQ 1 year postprocedure in 69% of the cohort, and reported resolution of behavioral problems in the
entire cohort; complications include weight gain, postprocedure precocious puberty, and pituitary dysfunction.15
LITT achieves 93% seizure freedom at 12 months46; however, it can be associated with salt wasting with treatment of
larger HH.47,e27,e28 In a series of 18 patients undergoing
LITT, complications included weight gain (22%), short term
memory loss (22%), and delayed hypothyroidism (11%).48
The (surface) laser probe used in endoscopic procedures
(distinct from that used during laser interstitial thermal
therapy) is applied under direct visualization without intraoperative imaging feedback.49 MRI-guided focused ultrasound thermoablation is a newer noninvasive method being
studied. There are also open microsurgical techniques
Neurology.org/N

Figure 2 MRI Examples of Delalande Classification of Hypothalamic Hamartoma (HH)

All panels show coronal T2-weighted MRI. HH lesion type is
designated according to the proposed classification system of
Delalande and Fohlen.44 (A) Type I HH: 2-year-old boy with
mild developmental delay but otherwise asymptomatic. Note
attachment of the HH lesion entirely below the floor of the
third ventricle. (B) Type II HH: 5-year-old boy with a history of
gelastic seizures since 12 months of age. Note attachment to
the left side of the hypothalamus, entirely above the floor of
the third ventricle. (C) Type III HH: 31-year-old woman with
refractory epilepsy, including gelastic seizures since infancy.
Note attachment of the HH lesion to the right side of the hypothalamus both above and below the floor of the third
ventricle. (D) Type IV HH: 3-year-old girl with severe developmental delay, history of precocious puberty, and multiple daily gelastic seizures. Type IV is designated by Delalande
and Fohlen as a “giant” HH, but criteria to distinguish between
types III and IV were not offered. We (Barrow Neurologic Institute) currently use a volume measurement over 8 cm3 to
designate type IV, measuring the maximal length of the lesion
in the 3 major axes, then utilizing the formula for determining
the volume of an ellipsoid (courtesy of John F. Kerrigan, MD,
Barrow Neurologic Institute).

including transcallosal resection, orbitozygomatic approach,50 transventricular, transcortical, and pterional
approaches for the surgical treatment of HH; the orbitozygomatic and pterional approaches may have higher risk
than other approaches. There has been a trend away from
open microsurgical techniques (such as the original Australian transcallosal approach) to more minimally invasive
techniques such as laser interstitial thermal therapy, SRT,
and focused ultrasound as success is high and surgical
morbidity reduced. In a cohort of 26 patients with HH
treated with transcallosal resection, 88% of patients had
behavioral improvement; 58% had transient postoperative
memory dysfunction and 65% had overall improvement.38
A smaller study of 10 patients treated with orbitozygomatic resection, not suitable for lesions below the IIIrd
ventricular ﬂoor, had 80% improvement in overall quality
of life, and 33% of patients experienced improvements in
presurgical behavioral and mood problems. 50 It is postulated that many of the presurgical memory problems relate
to HH and proximity to the mammillary bodies; increased
anterior–posterior extension around the mammillary
bodies is associated with increased risk of cognitive
problems. 51 Surgical techniques, such as endoscopic or
microsurgical transcallosal approaches, can incur forniceal
contusion, which is related to postoperative memory
dysfunction. 52

Neurology.org/N

A cross-sectional comparative surgical eﬀectiveness feasibility
study from 14 international centers of 94 patients (mean 11.8
years, range 1 to 69 years of age) was performed in 2019 on
children who underwent epilepsy surgery in 2014–2015. This
study did not identify a clear distinction among surgical approaches but demonstrates the need for larger studies and
provided evidence of feasibility to that goal (Hesdorﬀer et al.,
unpublished data). Prospective collection of short- and longterm adverse eﬀects of various surgical procedures is important
as these have likely been underestimated by present studies.
Physiologic characteristics of HH and the nearby hypothalamus that might aﬀect surgical outcome were studied, but
the need for an adequate anatomical disconnection of the
HH from the surrounding brain was highlighted. Restingstate functional MRI studies identify diﬀerent connectivity
patterns by independent component analysis. These may
identify any HH voxel that is functionally connected to other
non-HH tissue, which is thought to indicate aberrant and
potential pathways for seizure propagation, and correspond
to regions of initial ictal propagation by stereo-EEG; their
targeted ablation may improve seizure outcome.53,54 The
unique electrophysiologic characteristics of both the HH
and the nearby normal hypothalamus were also studied, and
those ﬁndings potentially correlated with the area to be
resected/disconnected.55
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Ictal surface EEG may deceptively suggest a cortical focus,
which likely represents spread from the HH. Using simultaneous stereo-EEG, multiple seizure types were found to
originate in HH with later spread to cortical regions.56 Seizure
freedom is associated with removal or disconnection of the
HH; cortical resection of presumed epileptogenic areas does
not achieve seizure freedom.
Human HH slices are being used for in vivo modeling in
candidate drug development. One novel therapeutic target is
the cannabinoid receptor 2 (CB2), which has been shown to
be overexpressed in HH. Using this model, CB2 agonists
decreased epileptiform activity and thus may represent a new
potential therapy for HH-associated epilepsy (Wu, unpublished data).

Insights From Other
Encephalopathies
There is precedent for molecular treatment of other epileptic encephalopathies, either in tumors from the same
region or other genetic syndromes that can show improvement with pathway-speciﬁc targeting. Advances in
molecular genetics allow for precision therapy of other tumors
in the sellar region. For example, there are therapeutic discoveries in low-grade glioma (LGG) with molecular inhibitor
therapy targeting the BRAFV600E mutation.57 LGG can present
as a hypothalamic tumor with a diencephalic syndrome causing
encephalopathy that improves or resolves with tumor treatment. Similarly, there are advances in the molecular targeting (everolimus, sirolimus) of the mTOR pathway for the
treatment of tuberous sclerosis. While a study in older
children of mTOR inhibition failed to demonstrate cognitive
improvement,58 some investigators hypothesize that mTOR
inhibition in young children may help prevent or reverse
encephalopathy in tuberous sclerosis complex. Thus, the
expansion of the molecular genetics underlying HH may
provide similar targeted therapies, and the possibility of
improved cognitive outcomes. Such targeted therapies could
include SMO inhibitors like vismodegib that reduce activation of hedgehog pathway signaling.59 Vismodegib is approved for clinical use with demonstrated eﬃcacy for lesion
shrinkage or cessation of new lesion development in basal
cell naevus syndrome.e29 Future prospective studies should
incorporate neuropsychological outcomes to formally address this issue.

Future Directions
Development of Standardized
Management Guidelines
Care for children with HH is not consistent despite centerspeciﬁc expertise. Standardized pre- and postoperative diagnostic, treatment (including timing and selection of surgical
approach), and management guidelines for both children and
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adults by specialty for neurology, neuropsychology/psychiatry,
endocrinology, and imaging will improve care.
Tissue is important for further characterization of somatic
mutations and to determine cellular origin of HH. It may be
possible to recover HH cells and their DNA from laser ablation probes by adapting a new method developed for stereoEEG electrodes.e10 Furthermore, in vivo models may prove
helpful in understanding the pathogenesis of HH. In the rodent models under development, in utero electroporation or
tamoxifen is used to transiently induce expression of somatic
protein truncating GLI3 mutations that are known to cause
HH in humans (West et al., unpublished data).
Another priority is to characterize a cardinal feature of HH
encephalopathy: rage attacks as a distinct feature of HH. A
rating/evaluation scale will be important to create and validate
for further objective assessment. Another area of focus would
be the study of memory dysfunction in HH given the closeness of the hypothalamus to local and remote memory
structures (mammillary bodies and more remote memory
circuits, e.g., prefrontal cortex).34 Other topics of interest
include (1) researching the relationship between intellectual
or developmental disability, behavior, and seizure control as
seizure control may not result in improved behavior; (2)
development of pre- and postsurgical psychiatric proﬁling;
(3) better diagnosis/treatment of ADHD/autism spectrum
disorder in HH; (4) exploring longitudinal study for psychiatric comorbidity; (5) evaluating support and intervention for
managing complex behavioral health issues; and (6) directly
comparing the available surgical options.
The question of SUDEP and SUDEP risk needs to be elucidated. Generalized tonic-clonic seizures, a risk factor for
SUDEP, are relatively rare in HH. Thus, HH may provide
insights regarding SUDEP mechanisms given several anatomical projections from the hypothalamus and functional
connection from the HH to the tectum and brainstem
structures were recently implicated in SUDEP models.60
There is also a need for a coordinated, prospective observational study with standardized assessments and measures to
identify the diﬀerential eﬀect of therapies on seizure control,
encephalopathy, and comorbidities including investigation of
early resection/disconnection/ablation on expression of
encephalopathy.

Discussion
HHs are often small, suprasellar masses that can lead to
devastating epileptic encephalopathy and comorbidity. The
past 2 decades have seen advances in the understanding and
management of HH and its comorbidities, with the potential
to prevent or reverse the devastating consequences of this
disease in some patients. HH presents in 2 ways: the intrahypothalamic variant presents with pharmacoresistant
Neurology.org/N

epilepsy (including gelastic seizures), neurocognitive and
behavioral sequelae, and endocrine dysfunction. The parahypothalamic variant (seen in syndromic HH such as in
PHS) usually causes central precocious puberty, but these
patients do not develop severe neurologic comorbidities or
epilepsy. The mutations underlying development of syndromic PHS are thought to be in GLI3, whereas only a subset
of the mutations causing nonsyndromic HH are in GLI3,
with variants in other hedgehog and cilia genes still being
discovered. The exact mechanisms underlying the development of the severe epilepsy syndrome, encephalopathy, and the neurocognitive/behavioral sequelae (including
rage) remain elusive. Progress is being made with in vitro
and in vivo modeling, molecular genetic analyses, surgical
and ablative therapies, as well as broader studies on the
neurocognitive and behavioral eﬀects of the disease and its
treatment.
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